Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1968 2
1971 1
1972 1
1974 1
1975 1
1976 2
1977 4
1978 3
1980 9
1981 6
1982 7
1983 11
1984 14
1985 14
1986 10
1987 22
1988 16
1989 28
1990 36
1991 38
1992 56
1993 46
1994 69
1995 62
1996 77
1997 61
1998 75
1999 82
2000 108
2001 103
2002 111
2003 125
2004 135
2005 139
2006 178
2007 211
2008 201
2009 208
2010 282
2011 307
2012 353
2013 434
2014 475
2015 592
2016 677
2017 807
2018 947
2019 1100
2020 1223
2021 1258
2022 1119
2023 1107
2024 375

Text availability

Article attribute

Article type

Publication date

Search Results

11,827 results

Results by year

Filters applied: . Clear all
Page 1
Lung cancer immunotherapy: progress, pitfalls, and promises.
Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, Mukherjee A, Paul MK. Lahiri A, et al. Mol Cancer. 2023 Feb 21;22(1):40. doi: 10.1186/s12943-023-01740-y. Mol Cancer. 2023. PMID: 36810079 Free PMC article. Review.
Lung cancer is the primary cause of mortality in the United States and around the globe. ...Recent trials on lung cancer patients (without a targetable oncogenic driver alteration) reveal significant and sustained responses when treated with programmed …
Lung cancer is the primary cause of mortality in the United States and around the globe. ...Recent trials on lung ca …
Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism.
Yin J, Wu Y, Yang X, Gan L, Xue J. Yin J, et al. Front Immunol. 2022 Apr 7;13:830631. doi: 10.3389/fimmu.2022.830631. eCollection 2022. Front Immunol. 2022. PMID: 35464480 Free PMC article. Review.
Immune checkpointty inhibitors (ICIs), particularly those targeting programmed death 1 (PD-1) and anti-programmed death ligand 1 (PD-L1), enhance the antitumor effect by restoring the function of the inhibited effector T cells and produce …
Immune checkpointty inhibitors (ICIs), particularly those targeting programmed death 1 (PD-1) and anti-programme …
PD-L1 Expression in Lung Cancer.
Yu H, Boyle TA, Zhou C, Rimm DL, Hirsch FR. Yu H, et al. J Thorac Oncol. 2016 Jul;11(7):964-75. doi: 10.1016/j.jtho.2016.04.014. Epub 2016 Apr 23. J Thorac Oncol. 2016. PMID: 27117833 Free PMC article. Review.
Immunotherapies targeted against programmed death ligand 1 (PD-L1) and its receptor (PD-1) have improved survival in a subset of patients with advanced lung cancer. ...The understanding of PD-L1 as a biomarker is complicated by the …
Immunotherapies targeted against programmed death ligand 1 (PD-L1) and its receptor (PD-1) have improved surviva …
First-Line Immunotherapy for Non-Small-Cell Lung Cancer.
Reck M, Remon J, Hellmann MD. Reck M, et al. J Clin Oncol. 2022 Feb 20;40(6):586-597. doi: 10.1200/JCO.21.01497. Epub 2022 Jan 5. J Clin Oncol. 2022. PMID: 34985920 Review.
For patients with metastatic non-small-cell lung cancer (mNSCLC), the last decade has been characterized by critical progress that has contributed to substantially improved survival. ...Although clinical development of immune checkpoint inhibitors with anti- …
For patients with metastatic non-small-cell lung cancer (mNSCLC), the last decade has been characterized by critical progress …
PARP inhibitor plus radiotherapy reshapes an inflamed tumor microenvironment that sensitizes small cell lung cancer to the anti-PD-1 immunotherapy.
Zhang N, Gao Y, Huang Z, Dai P, Luo Y, Wu Q, Jiang X, Sun W, Zhang J, Han L, Zhang J, Gong Y, Xie C. Zhang N, et al. Cancer Lett. 2022 Oct 1;545:215852. doi: 10.1016/j.canlet.2022.215852. Epub 2022 Aug 1. Cancer Lett. 2022. PMID: 35926817
Small cell lung cancer (SCLC) is a highly malignant tumor with extremely poor prognosis. ...Together, our studies demonstrated that PARP inhibitor combined with RT potentiated anti-tumor immunity and enhanced the efficacy of anti-PD-1 imm …
Small cell lung cancer (SCLC) is a highly malignant tumor with extremely poor prognosis. ...Together, our studies demonstrated …
Lung cancer patients with chronic obstructive pulmonary disease benefit from anti-PD-1/PD-L1 therapy.
Lin M, Huang Z, Chen Y, Xiao H, Wang T. Lin M, et al. Front Immunol. 2022 Dec 1;13:1038715. doi: 10.3389/fimmu.2022.1038715. eCollection 2022. Front Immunol. 2022. PMID: 36532019 Free PMC article. Review.
Lung cancer (LC) and chronic obstructive pulmonary disease (COPD) are two of the most fatal respiratory diseases, seriously threatening human health and imposing a heavy burden on families and society. ...With the development of immune checkpoint inhibition (ICI) th …
Lung cancer (LC) and chronic obstructive pulmonary disease (COPD) are two of the most fatal respiratory diseases, seriously th …
Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer.
Wang L, Yang Z, Guo F, Chen Y, Wei J, Dai X, Zhang X. Wang L, et al. Front Immunol. 2023 Jul 3;14:1227797. doi: 10.3389/fimmu.2023.1227797. eCollection 2023. Front Immunol. 2023. PMID: 37465684 Free PMC article. Review.
Currently, anti-PD-1/PD-L1 immunotherapy using immune checkpoint inhibitors is widely used in the treatment of multiple cancer types including lung cancer, which is a leading cause of cancer death in the world. ...In this re …
Currently, anti-PD-1/PD-L1 immunotherapy using immune checkpoint inhibitors is widely used in the treatment of m …
Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer.
Cho JW, Hong MH, Ha SJ, Kim YJ, Cho BC, Lee I, Kim HR. Cho JW, et al. Exp Mol Med. 2020 Sep;52(9):1550-1563. doi: 10.1038/s12276-020-00493-8. Epub 2020 Sep 2. Exp Mol Med. 2020. PMID: 32879421 Free PMC article.
Therefore, strategies for improving the response to PD-1 inhibitor for treating various cancers including non-small cell lung cancer (NSCLC) are urgently needed. ...We found that eDMRs contribute to the epigenetic regulation of the anti-PD …
Therefore, strategies for improving the response to PD-1 inhibitor for treating various cancers including non-small cell lu …
PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance.
Huang C, Ren S, Chen Y, Liu A, Wu Q, Jiang T, Lv P, Song D, Hu F, Lan J, Sun L, Zheng X, Luo X, Chu Q, Jia K, Li Y, Wang J, Zou C, Hu J, Wang G. Huang C, et al. Sci Adv. 2023 May 26;9(21):eade4186. doi: 10.1126/sciadv.ade4186. Epub 2023 May 26. Sci Adv. 2023. PMID: 37235656 Free PMC article.
Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) or programmed cell death 1 ligand 1 (PD-L1) have enabled some patients with cancer to experience durable, complete treatment responses; however, reliable …
Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) or programmed cell death 1 ligand …
Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer.
Xie C, Zhou X, Liang C, Li X, Ge M, Chen Y, Yin J, Zhu J, Zhong C. Xie C, et al. J Exp Clin Cancer Res. 2021 Aug 24;40(1):266. doi: 10.1186/s13046-021-02069-4. J Exp Clin Cancer Res. 2021. PMID: 34429133 Free PMC article.
BACKGROUND: Recently, a variety of clinical trials have shown that apatinib, a small-molecule anti-angiogenic drug, exerts promising inhibitory effects on multiple solid tumors, including non-small cell lung cancer (NSCLC). ...Apatinib also inhibited PD …
BACKGROUND: Recently, a variety of clinical trials have shown that apatinib, a small-molecule anti-angiogenic drug, exerts promising …
11,827 results
You have reached the last available page of results. Please see the User Guide for more information.